EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Concord Biotech's enterprise value is ₹155,078 Mil.
Concord Biotech's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was ₹4,671 Mil. Therefore, Concord Biotech's EV-to-EBITDA for today is 33.20.
The historical rank and industry rank for Concord Biotech's EV-to-EBITDA or its related term are showing as below:
BOM:543960'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 25.52 Med: 37.78 Max: 45.2
Current: 33.2
During the past 4 years, the highest EV-to-EBITDA of Concord Biotech was 45.20. The lowest was 25.52. And the median was 37.78.
BOM:543960's EV-to-EBITDA is ranked worse than 81.86% of 463
companies
in the Biotechnology industry
Industry Median: 9.32
vs BOM:543960: 33.20
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Concord Biotech EV-to-EBITDA Historical Data
The historical data trend for Concord Biotech's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Concord Biotech's EV-to-EBITDA
For the Biotechnology subindustry, Concord Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Biotech's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Concord Biotech's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Concord Biotech's EV-to-EBITDA falls into.
Concord Biotech's current Enterprise Value is ₹155,078 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Concord Biotech's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was ₹4,671 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Concord Biotech's PE Ratio for today is calculated as:
Concord Biotech's share price for today is ₹1504.20.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Concord Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was ₹29.091.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Concord Biotech's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Concord Biotech Ltd is a Research & development-driven biopharma Company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BOM:543960 has been successfully added to your